Category: 3. Business

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Accenture has started calling its nearly 800,000 employees “reinventors”, as the consultancy overhauls itself to adapt to the explosion of artificial intelligence and advises companies adopting the technology.

The label has already been used by chief executive Julie Sweet and the New York-listed group is pushing to have the term adopted more widely, according to people at the firm.

The term “reinventors” was born from a mammoth reorganisation announced by the consultancy in June, which united its strategy, consulting, creative, technology and operations units into a single business called “Reinvention Services”.

The rollout of the neologism follows a long tradition of corporate jargon to describe employees, including Disney’s “imagineers” and Amazon’s “ninja coders”.

Accenture has said its ambition is to be clients’ “reinvention partner of choice” by helping them to adopt AI tools.

On a September earnings call, Sweet referred to employees as “reinventors” multiple times as she discussed the reorganisation.

She also warned that more staff would be asked to leave if they could not be retrained for the age of AI amid more sluggish demand for consulting projects.

The consultancy has built a trial version of its internal human resources website in which staff are labelled “reinventors” rather than “workers”, according to a person familiar with the matter.

The company has a history of creating its own corporate language. Its name, intended as a derivative of “accent on the future”, was ridiculed when it was adopted in 2001 after the business, Andersen Consulting, broke ties with accounting group Arthur Andersen and was forced to change its name. The rebrand was reported to have cost $100mn.

Accenture’s market capitalisation surged to more than $260bn during a boom in demand for consulting services following the Covid-19 pandemic, but has since fallen to about $150bn as the sector faces a growth slowdown.

“Jargon is used in the consulting world to signal expertise or relevance without having to invest in underlying competencies and knowledge . . .[or make] boring or staid jobs or processes appear to be novel and exciting,” said André Spicer, executive dean and professor of organisational behaviour at the Bayes Business School and author of Business Bullshit. 

He warned that while jargon can occasionally boost an organisation’s image and its confidence internally, it also “increas[es] confusion, undermining trust and fostering a sense of corporate absurdity”.

Big Four accounting firm PwC in 2002 briefly rebranded its consulting division as “Monday” but the name was dropped when IBM bought the unit. PwC pointed out in a statement at the time that its unusual new name is “a real word”, seen by some commentators as a dig at Accenture.

Deborah Cameron, former professor of language and communication at Oxford university, said that using terms for staff that are “so out of step with what most people think your business is” risked attracting “incomprehension or ridicule”.

The term “reinventors might be getting into that territory”, she said. “Will clients, or the public at large, know what they’re supposed to be reinventing? Will employees themselves . . . feel OK saying they’re reinventors, or will they find that obscure, pretentious and silly?”

Accenture declined to comment.

Africa stands at a crossroads in the flow of global energy dynamics — a pivotal moment where the continent can leverage its abundant fossil fuel resources for equitable development. To ensure this outcome, stakeholders must concentrate investment on key areas like refining capacity, trading networks, and adoption of cleaner fuels if Africa is to be prepared for the 2050 projections covered in the African Energy Chamber’s (AEC) 2026 Outlook Report, “The State of African Energy.”

Africa’s need for refined products is set to surge, driven by demographic and economic forces. According to our report, Africa’s refined product demand is projected to climb from approximately 4 million barrels per day (bbl/d) in 2024 to over 6 million bbl/d by 2050.

While many advanced economies are moving to reduce their dependence on oil and gas, Africa is next in line to benefit from its own — and has every right to do so, just as the developed nations of the world already have. This situation highlights both the opportunities for energy security and the challenges that lie ahead regarding infrastructure development.

A Unique Trajectory

While many other regions around the world are expected to follow the same path toward green alternatives as Europe and North America in the coming years, Africa’s oil demand shows no sign of waning anytime soon. However, Africa’s trajectory is markedly different: Per capita consumption remains the lowest globally, particularly in sub-Saharan African nations, leaving substantial room for expansion as populations and GDPs rise.

Forecasts suggest that the continent’s population could swell by more than 930 million people, reaching nearly 2.4 billion by 2050. This would account for 25% of the world’s population and 63% of global population growth between now and then.

Economic projections are equally substantial, with Africa’s 2050 GDP expected to nearly triple from what it is now to around USD7.8 trillion after growing at a compound annual growth rate (CAGR) of 3.8-3.9% in the coming decades. Smaller, less developed markets will lead this charge, amplifying demand for energy-intensive activities.

Currently, despite representing 18% of the global population, Africa consumes less than 5% of the world’s oil products and contributes just 3% to global GDP.

This disparity indicates untapped potential.

As the 2026 Outlook Report emphasizes, Africa’s oil demand will continue growing to 2050 and beyond, fueled by population growth, industrialization, and urbanization. Furthermore, while sub-Saharan Africa’s per capita oil demand is the world’s lowest, there is a dire need for an increased supply of oil and gas products, positioning the region as an engine for long-term growth.

Gasoline: Global Growth Will Be African

Africa is poised to become the primary driver of worldwide gasoline demand growth over the long term, offsetting declines in China and member countries of the Organisation for Economic Co-operation and Development (OECD). Our report projects that Africa’s gasoline consumption will exceed 2.2 million bbl/d by 2050, with Nigeria and emerging markets at the forefront.

Nigeria already dominates continental gasoline demand, yet its per capita usage is still comparatively low. In established markets like Algeria, Morocco, Egypt, and South Africa, demand is expected to stagnate in the early 2040s due to overall improving fuel economy, the rise of compressed natural gas (CNG)/liquefied petroleum gas (LPG) vehicles in Egypt and Algeria, and electric vehicle (EV) adoption in South Africa.

The spotlight on the transportation sector in our 2026 Outlook Report reveals that the continent’s overall gasoline needs will still rise over the next 25 years as the prevalence of gasoline-powered light-duty vehicle fleets is not expected to wane. Though alternative powertrains like EVs will penetrate the market, they’ll do so slowly due to the inadequate electricity supply and the scarcity of a charging infrastructure. Therefore, gasoline will remain the backbone of personal and commercial mobility, especially in the less developed regions where economic activity requires road transport.

Diesel/Gasoil: Fueling Industrial and Extractive Expansion

Diesel/gasoil will see even more pronounced growth, with consumption expected to increase by about 880,000 bbl/d by 2050, nearly 50% from current levels, and growing to just under 2.7 million bbl/d. This positions Africa as the top growth region for the product, surpassing Latin America.

Beyond road transport, demand will be propelled by the extractive industries. Investments in critical minerals that support energy transition (e.g., lithium, cobalt, and nickel) are accelerating in mineral-rich Central and Southern Africa. Much of the growth in demand for diesel/gasoil will come from countries like Angola, the Democratic Republic of Congo (DRC), Zambia, and Zimbabwe. Development in the Copperbelt region between Zambia and the DRC, with initiatives like the Lobito Corridor project, will intensify diesel needs for mining operations and power generation.

Private and commercial trucking will further contribute, as population and GDP growth will necessitate an increase in the transportation of goods in general. Unlike gasoline, diesel’s versatility in heavy-duty applications will ensure a sustained demand, even as cleaner alternatives emerge in other sectors.

Aviation Fuels: Recovery and Long-Term Ascent

Jet fuel and kerosene demand is on the verge of a strong rebound in Africa with expectations that it will surpass its pre-COVID levels in 2025. Inter- and intra-regional air travel is regaining momentum, with consumption projected to top 280,000 bbl/d this year and increase 65% by 2050, reaching a rate of 465,000 bbl/d.

Along with population expansion, this growth will stem from tourism, business travel, the gradual growth of an urban middle class, and infrastructure investments. Projects like Ethiopia’s new airport southeast of Addis Ababa and the African Continental Free Trade Area (AfCFTA) will enhance connectivity, increasing passenger air travel and freight transport.

A Cleaner Cooking Solution with Untapped Potential

Amid rising demand for refined products, LPG as a cooking fuel is the standout opportunity for cleaner energy. Our 2026 Outlook Report identifies LPG as the most abundant and practical alternative to traditional biomass and coal for African households as it offers health and environmental benefits as well as a means of reducing emissions.

Today, over 900 million Africans lack access to clean cooking solutions, relying on wood, dung, coal, or paraffin — fuels that cause toxic indoor pollution, deforestation, and high greenhouse gas emissions. The switch to LPG would reduce particulate matter by 98% and save 1.2 million hectares of forest annually (a quarter of global deforestation). More importantly, this would also reduce the number of deaths and the prevalence of the devastating health conditions that these particulates cause. The conversion to LPG cooking would also cut black carbon emissions by 117 million tonnes of CO2 equivalent each year. Overall, CO2 reductions could reach 279 million tonnes per year, an amount comparable to the total emissions of mid-sized nations like Taiwan or Malaysia.

Despite these advantages, LPG use remains low at under 20 million tonnes per year. Our report, based on S&P Global Commodity Insights data as of June 2025, predicts only modest growth, with Nigeria, Morocco, Egypt, South Africa, Algeria, and others contributing to a slight rise as we head toward 2050.

Barriers and Pathways Forward

The modest projections in our report can be attributed to persistent policy and infrastructure hurdles. Regulatory frameworks, consumer financing plans, and distribution networks in rural and low-income areas would all need development. Without targeted investments, demand will remain suppressed.

The upside potential is significant, however. Countries like Kenya, Nigeria, and Côte d’Ivoire demonstrate that, with supportive policies, LPG adoption can accelerate. As our report suggests, if the latent demand for LPG was unleashed, projected consumption in 2050 could more than double from current forecasts.

Africa’s surge in demand for refined products is a multifaceted issue that will require proactive planning. Over USD20 billion in downstream infrastructure investment is needed by 2050 to handle imports and distribution. Flagship projects like Nigeria’s Dangote refinery are vital but insufficient on their own, and the smaller initiatives we are seeing in Angola and Uganda won’t bridge the gap.

As our 2026 Outlook Report illustrates, Africa’s energy future is one of tremendous growth. To ensure that this future will be prosperous and support the growing needs of all Africans, policymakers, investors, and international partners must prioritize efficient trading, local refining, and a transition to fuels like LPG to maximize value for the continent’s 2.4 billion people by mid-century.

“The State of African Energy: 2026 Outlook Report” is available for download. Visit https://energychamber.org/report/the-state-of-the-african-energy-2026-outlook-report to request your copy.

The Mashable shopping team generally considers Black Friday to be a better shopping day than Cyber Monday, but only by a hair. While most holiday deals that pop up on Black Friday tend to linger through Cyber Monday, the selection is best early on, and only in rare cases do discounts improve over the course of the weekend. When it does happen, we want to make sure our readers are clued in.

So far, my colleagues and I have stumbled upon nine Black Friday deals at Amazon and Best Buy that have gotten better now that both retailers are in Cyber Monday mode. Most of the price discrepancies are pretty significant, too. In the biggest instance, Samsung’s 55-inch The Frame 4K QLED TV is a whopping $100 cheaper on Amazon now compared to 48 hours ago. Meanwhile, it’s $102 pricier at Best Buy and Samsung’s website.

If you purchased one of these items at a higher price and want to get reimbursed for the difference, keep in mind that price protection policies vary from retailer to retailer. Best Buy will honor better deals on almost anything you’ve bought there since Oct. 31, but Amazon doesn’t offer any sort of price adjustments. You’ll need to return and rebuy previous Amazon purchases that are now cheaper. (My take: Most of the following deals are definitely worth the hassle.)

“The clinical benefits of Verida will fundamentally change my approach to cardiac imaging,” said Prof. Eliseo Vañó Galván, cardiovascular radiologist, Chairman of the CT & MR Department at Hospital Nuestra. Sra. Del Rosario, Madrid, Spain. “With more comprehensive insights in every cardiac CT, I plan to make spectral imaging routine for all patients – building toward a fully spectral CT department. We evaluated many systems, including photon-counting CT, but chose Philips because it delivers the precision we need in a streamlined, easy-to-use platform. The result is greater diagnostic confidence and the potential to reduce the need for invasive angiograms – not just in cardiology, but across other clinical areas as well [7].”

Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than before and enabling up to 270 exams every day [8]. Building on Philips’ proprietary Spectral Precise Image technology – a deep learning AI reconstruction engine combined with advanced spectral imaging – and its third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction optimized for AI, Verida is designed to deliver faster, more dose-efficient spectral reconstructions. This enables clinicians to access rich spectral information from a single scan.

“Combining the latest advances in our proven spectral CT technology with AI, our flagship Verida CT system is designed to set a new standard in superior image quality and accelerated scans which are fully embedded in the radiology workflow, all to help clinicians detect and characterize disease earlier, reduce variability in diagnoses, and support efficient treatment pathways – in a single scan,” said Dan Xu, Business Leader of CT at Philips. “While photon-counting CT adds complexity, is yet to move from the research arena into clinical practice, Philips spectral CT has been a clinical workhorse for more than a decade and delivers comparable or better clinical outcomes, standing up to the most demanding throughput and at significantly lower total cost of ownership”. 

Verida extends Philips’ software-defined CT approach, pairing AI-driven spectral precision to advance both clinical and operational outcomes. Built for high-demand environments, it streamlines workflows, reduces repeat scans, and delivers consistently sharp imaging across all care pathways.

Philips is debuting Verida at RSNA 2025, with availability in select markets beginning in 2026 [9].

Next-generation clinical AI on the Philips BlueSeal Horizon platform

Philips will bring next-generation clinical AI into everyday practice with the introduction of its new BlueSeal Horizon MR platform [1], simplifying workflows, enhancing diagnostic precision, and expanding access to advanced imaging. Key AI-powered innovations will include:
 

• SmartPlanning: Expanding to include cardiac imaging, this AI-driven feature will automate time-consuming planning steps. What once required multiple manual actions can now be completed in a single click, achieving automated planning in as little as 30 seconds. 
• Real-time Scan Preview: Powered by NVIDIA’s accelerated computing platform and Open Models (Segment and Generate), this innovation aims to enable faster 3D image reconstruction, denoising, and artifact reduction, so radiologists can preview scans, adjust image quality and speed parameters in real time, and optimize workflow efficiency for more timely diagnosis.
• SmartSpeed Precise: Dual AI technology will enable scans up to three times faster and images up to 80% sharper [4], helping clinicians capture more detail in less time. 
• SmartReading: This tool will integrate cloud-based AI reading and reporting tools directly on the MR system, specifically for neurology and oncology applications.

Together, these innovations will bring advanced clinical AI to the point of care, helping radiology teams achieve faster, sharper, and more consistent imaging results, supporting confident, first-time-right diagnosis. 

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

In 2025, Indonesia and China marked the 75th anniversary of their diplomatic ties, highlighting how the relationship has matured into one of the Indo-Pacific’s most consequential. The commemoration signals not merely symbolism but the growing weight of a partnership that is expanding in trade, investment, and defence. At the same time, both states navigate cooperation alongside the imperative of maintaining autonomy.

For Beijing, Indonesia functions as a strategic partner and hub which an economic centre of gravity securing critical mineral supply chains for electric vehicles and renewable industries. Indonesia relations also serve as a geopolitical buffer on the southern flank of the South China Sea and key energy corridors to the Indian Ocean. Indonesia is seen as a pivotal Global South actor that can bolster China’s nonalignment narrative in platforms such as the United Nations, G20, and BRICS+.

Bilateral trade in 2024 reached US$135 billion, making China Indonesia’s largest trading partner. China is also the country’s second-largest foreign investor, investing in various sectors, including energy, smelters, and transportation infrastructure. During Prabowo Subianto’s state visit to Beijing in November 2024, both governments agreed on new investment commitments worth US$10 billion, covering mineral downstreaming, renewable energy, and digital infrastructure.

This indicates that Indonesia’s exports to China remain heavily reliant on critical minerals and commodities – with minimal technological value added. The reliance on Chinese inputs means that much of Indonesia’s industrial expansion, as stated in the government’s downstreaming policy, largely depends on the stability of Chinese supply chains.

Prabowo retains key policy instruments to recalibrate Indonesia’s position.

Significant Chinese investments in Indonesia’s critical minerals and renewable energy sectors have created path dependency, as much of the technological know-how Indonesia sought to acquire for its economic transformation is 75% controlled by Chinese companies. Since these projects rely on Chinese raw materials or midstream processing, this keeps Jakarta’s critical minerals industrial ecosystem tied to Beijing’s technological and financial orbit. Recent developments – including South Korea’s LG Energy Solution withdrawal and the likelihood of its replacement by a Chinese company – indicate that competitive pressure on Chinese firms remains limited and may even be narrowing. Still, this would not change the underlying dependence of Indonesia’s downstream industries on Chinese technology, capital, and supply chains.

Ironically, what the Indonesian government often touts as quick wins – high-speed rail, industrial parks, battery factories – are merely the local face of a global chain controlled by Beijing. In this framework, Indonesia’s economic sovereignty is not a matter of ownership, but rather the extent to which it can break free from Beijing’s orbit without incurring excessive political and social costs.

In this overall strategy, it is clear that Beijing has chosen a path of “tying up” Indonesia rather than putting it under its sphere of influence. Instead of formal alliances, Beijing relies on these long-term linkages to ensure that Indonesia does not drift too far away from its orbit. As long as strategic minerals and downstream industries in Indonesia remain based on Chinese technology, and as long as Indonesia remains engaged with the Shanghai Cooperation Organisation (SCO) – signified by Indonesia’s first-ever attendance at this year’s SCO leaders’ summit in Tianjin – Beijing does not need to open a new imprint in Southeast Asia.

For Beijing, Indonesia is likely to remain closely tied to China so long as the costs of reducing Jakarta’s economic and technological dependence outweigh the benefits of diversification. However, this trajectory is not predetermined. While President Prabowo Subianto has signalled that economic cooperation with China will continue, Indonesia is inviting other countries such as Australia and the United States to invest in Indonesia’s critical minerals industry, to ensure that the supply chain is not completely dependent on investment from China. However, so far this diversification strategy remains symbolic, since most projects still depend on Chinese technology and financing.

Nonetheless, Prabowo retains key policy instruments to recalibrate Indonesia’s position – tightening technology-transfer requirements, widening capital sources beyond EPC-driven projects, and reinforcing ASEAN-led frameworks that preserve open regional norms.

The Indonesian government may propose that technology transfer should be an integral part of future critical minerals and renewable energy investment from China. It should be subject to regular, independent evaluation and strict enforcement to ensure that Chinese projects generate not only physical infrastructure but also genuine skill diffusion among Indonesian engineers, data scientists, and other professionals. Jakarta can institutionalise this by conditioning investment approvals on clear R&D collaboration benchmarks and vocational training commitments with Chinese firms so that technological gains convert into domestic capability. Rather than deterring investment, such measures would enhance its credibility and long-term sustainability.

Whether Indonesia remains tied up or gradually redefines its trajectory in its economic relations with China will depend on how these instruments are used.

NeurologyLive® first published this article. This version has been lightly edited.

Recently reported data from the phase 2 portion of the KYSA-6 trial (NCT06193889) show that treatment with investigational KYV-101 (Kyverna Therapeutics), a CD19 chimeric antigen receptor (CAR) T-cell therapy, led to clinically meaningful responses in efficacy end points for patients with generalized myasthenia gravis (gMG). Overall, the data reinforce the potential of this novel therapeutic, which continues to be studied in the ongoing phase 3 portion of KYSA-6.^1,2

The trial, which was previously a phase 2 study but amended to phase 2/3, included patients aged 18 to 75 years with gMG, a history of acetylcholine receptor or muscle-specific kinase autoantibodies, and a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of at least 6. Presented at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, held October 29 to November 1, 2025, in San Francisco, California, the presentation featured 6 patients with moderate to severe gMG and an average disease duration of 5.3 years (range, 1.7-13.3) who were treated with a single dose of 1×108 KYV-101 CAR T cells.

At data cutoff, or up to 36 weeks, the 6 patients achieved clinically meaningful, robust, rapid, and sustained reductions in MG-ADL and Quantitative Myasthenia Gravis (QMG) scores, the dual primary outcomes, regardless of prior biologic exposure. Specifically, treated patients demonstrated mean reductions of –8.0 points on MG-ADL and –7.7 points on QMG at 24 weeks, with effects observed as early as 2 weeks post infusion.

“These unprecedented results validate our phase 3 trial design and underscore KYV-101’s potential to deliver durable, drug-free, disease-free remission by targeting the disease at its source through deep B-cell depletion,” Naji Gehchan, MD, MSc, MBA, chief medical and development officer at Kyverna, told NeurologyLive. “We’re eager to continue this progress to help address unmet needs for patients living with generalized myasthenia gravis.”

Efficacy data showed that all patients achieved at least a 3-point reduction in both MG-ADL and QMG, in addition to achieving a clinically meaningful response on Myasthenia Gravis Composite (MGC) scores. At 12 weeks, patients showed a mean reduction of –12 points on their MGC score, all while being free of nonsteroidal immunosuppressants, high-dose steroids, and neonatal Fc receptor and complement inhibitors.

In terms of safety, KYV-101 was shown to be well tolerated, with no new safety signals and 1 case of a serious adverse event (grade 4 neutropenia), which improved with standard supportive care and was downgraded to grade 1 at data cutoff. Notably, patients on the CAR T-cell therapy did not experience any high-grade cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome events throughout the study period.

Gehchan added, “While there are many approved therapies and new therapies under development for gMG, none have been able to address the underlying disease on a mechanistic level. With KYV-101, we are taking a novel, upstream approach to directly target the disease source by tapping into the patient’s own immune cells to fight disease.

“As an investigational CAR T-cell therapy, KYV-101 directly targets the disease source by deeply depleting the autoreactive B cells in tissues. In addition, KYV-101 has been shown to have a positive impact on a broader set of immune cell types and, in particular, regulatory T cells, which are essential for keeping the immune system in check.”

KYV-101, which is also being studied for other diseases, including progressive multiple sclerosis, received a regenerative medicine advanced therapy designation from the FDA in August 2024, further recognizing it as a promising treatment for gMG. The CAR in KYV-101 was designed by the National Institutes of Health to improve tolerability and was tested in a phase 1 trial (NCT02659943) in oncology with results published in Nature in 2020.³

The first-in-human study enrolled 20 patients with B-cell lymphoma and was designed primarily to evaluate safety and feasibility, with secondary assessments focused on blood levels, antilymphoma activity, the potential for second infusions, and immunogenicity. At the time known as Hu19-CD828Z T-cell therapy, KYV-101 met all of its study objectives. Patients treated with the therapy showed lower cytokine levels compared with those who received FMC63-28Z T cells, a finding investigators suggested could account for the reduced neurologic toxicity observed with the agent.

In early 2024, Kyverna reported the first individual treatments with KYV-101 in 2 patients with progressive multiple sclerosis. The therapy was well tolerated in the short term, showing CAR T-cell expansion in the cerebrospinal fluid without neurotoxicity and a reduction in intrathecal antibody production in 1 patient. Although both had previously received ocrelizumab, circulating B cells were detected only in patient 1, whose remaining B-cell population was depleted by day 2 and remained absent through day 100. Patient 1 also experienced a drop in oligoclonal bands (OCBs) from 13 to 6 by day 64, while patient 2 showed no changes in OCBs or intrathecal immunoglobulin levels.⁴

Gehchan concluded, “We believe KYV-101’s clinical profile provides us with an advantage. We anticipate a large effect size based on the first patients in the compassionate use pathway that has now been confirmed in this interim phase 2 readout. This enables us to have a more efficient study design with only about 60 patients to be randomized between standard of care and KYV-101. We are also including important [pharmokinetic] and [pharmacodynamic] end points like B-cell depletion and looking at effects on immune cell populations to help support our mechanistic approach that complements the other outcome assessments.”

References
1. Kyverna Therapeutics announces positive interim phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis at AANEM 2025. News release. Kyverna Therapeutics. October 29, 2025. Accessed November 19, 2025. https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-announces-positive-interim-phase-2-data
2. Muppidi S, Hunter MC, Hoffmann S, et al. Update on the phase 2 part of KYSA-6, an open-label, single-arm, multicenter study of KYV-101, a fully human CD19 chimeric antigen receptor T-cell therapy in generalized myasthenia gravis. Presented at: 2025 AANEM Annual Meeting. October 29-November 1, 2025; San Francisco, CA. Abstract 106.
3. Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Med. 2020;26(2):270-280. doi:10.1038/s41591-019-0737-3
4. Fischbach F, Richter J, Pfeffer LK, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550-558.e2. doi:10.1016/j.medj.2024.03.002